secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition II Corp. (DMII)
CIK:        0002040475
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001213900-25-111706
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud

Drugs Made In America Acquisition II Corp. appoints Saleem Elmasri as CFO after Glenn Worman resigns
--------------------------------------------------------------------------------

- Glenn Worman resigned as CFO and principal financial and accounting officer effective October 8, 2025, with no disagreement with the company.
- Saleem Elmasri was appointed CFO effective November 17, 2025, under a consulting agreement with Titan Advisory Services LLC.
- Compensation includes $42,000 per year ($3,500 per month) plus 100,000 ordinary shares transferred by CEO Lynn Stockwell.
- Elmasri is a CPA with 20 years experience, previously at PwC and as Managing Partner of Titan Advisory Services LLC since 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2040475/000121390025111706/0001213900-25-111706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2040475/000121390025111706/ea0265998-8k_drugs2.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-111706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer